Search

Your search keyword '"Veli-Jukka Anttila"' showing total 4 results
Start Over Author "Veli-Jukka Anttila" Journal alimentary pharmacology & therapeutics
4 results on '"Veli-Jukka Anttila"'

1. Letter: faecal microbiota transplantation for irritable bowel syndrome—which improvements are required? Authors' reply

Author

Perttu, Lahtinen, primary, Jonna, Jalanka, additional, Anna, Hartikainen, additional, Eero, Mattila, additional, Markku, Hillilä, additional, Jari, Punkkinen, additional, Jari, Koskenpato, additional, Veli‐Jukka, Anttila, additional, Jyrki, Tillonen, additional, Reetta, Satokari, additional, and Perttu, Arkkila, additional

Published
2020
Full Text
View/download PDF

2. Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. Authors' reply

Author

Reetta Satokari, Eero Mattila, Markku Hillilä, Anna Hartikainen, Jonna Jalanka, Perttu Arkkila, Jari Punkkinen, Veli-Jukka Anttila, Jari Koskenpato, Jyrki Tillonen, and Perttu Lahtinen

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Faecal microbiota transplantation, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, Pharmacology (medical), business, Irritable bowel syndrome
Published
2020
Full Text
View/download PDF

3. Letter: faecal microbiota transplantation for irritable bowel syndrome. Authors' reply

Author

Jyrki Tillonen, Jari Punkkinen, Jari Koskenpato, Perttu Lahtinen, Reetta Satokari, Eero Mattila, Perttu Arkkila, Anna Hartikainen, Veli-Jukka Anttila, Jonna Jalanka, and Markku Hillilä

Subjects
medicine.medical_specialty, Anemia, MEDLINE, Azathioprine, Gastroenterology, Faecal microbiota transplantation, Irritable Bowel Syndrome, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Pharmacology (medical), Irritable bowel syndrome, Leukopenia, Hepatology, business.industry, Fecal bacteriotherapy, Fecal Microbiota Transplantation, medicine.disease, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, medicine.symptom, business, medicine.drug
Published
2020
Full Text
View/download PDF

4. Rifaximin in the treatment of recurrentClostridium difficileinfection

Author

Eero Mattila, Päivi Tissari, Veli-Jukka Anttila, Perttu Arkkila, Petri S. Mattila, and Eveliina Tarkka

Subjects
Adult, Male, medicine.medical_specialty, medicine.drug_class, Antibiotics, Gastroenterology, Rifaximin, Young Adult, chemistry.chemical_compound, Anti-Infective Agents, Recurrence, Vancomycin, Metronidazole, Internal medicine, medicine, Humans, Pharmacology (medical), Colitis, Enterocolitis, Pseudomembranous, Aged, Retrospective Studies, Aged, 80 and over, Enterocolitis, Hepatology, Clostridioides difficile, business.industry, Rifamycin, Middle Aged, Clostridium difficile, medicine.disease, Rifamycins, Surgery, Treatment Outcome, chemistry, Clostridium Infections, Drug Therapy, Combination, Female, medicine.symptom, business, Follow-Up Studies, medicine.drug
Abstract

SummaryBackground Clostridium difficile can cause severe antibiotic-associated colitis. Conventional treatments with metronidazole and vancomycin improve symptoms, but after discontinuation of treatment, C. difficile infection (CDI) recurs in a number of patients. Rifaximin is a rifamycin-based non-systemic antibiotic that has effect against C. difficile. Aim To assess the effectiveness of rifaximin in recurrent C. difficile infection. Methods We retrospectively evaluated the records of 32 patients who were treated with rifaximin for recurrent C. difficile infection. The symptoms were evaluated 12 weeks after the start of treatment and patient records were followed up until 1 year after treatment. Results The mean age of the patients was 55 years (median 64, range: 19–84 years). Before the initiation of rifaximin therapy, the patients had undergone, on the average, 4.4 (range: 2–12) antimicrobial courses for C. difficile infection. C. difficile strain typing was performed in 27 patients. Eight (30%) patients had a strain with a DNA profile compatible with the BI/NAP1/027 ribotype. Antibiotic susceptibilities were determined of isolates from 22 patients. Most isolates (68%) had very low MIC-values for rifampin (

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results